Scrip

Progress Being Made With Cell And Gene Therapy Market Access, But Challenges Remain

By Mandy Jackson 14 Nov 2022

Drug developers and payers are coming together long before product approvals to work out payment options for high-cost, high-impact cell and gene therapies, but challenges like portability of commercially insured patients and Medicaid best price requirements remain.

Datamonitor Healthcare

Datamonitor Healthcare's Top Research Reports

27 Nov 2020

Scrip

Competitive Strategies Critical As EMA Decides On Kymriah And Yescarta

By Neena ​ Brizmohun 27 Nov 2020

With Novartis’s and Kite’s CAR T-cell therapies both expected to gain recommendations for pan-EU approval this week, discounts will need to be negotiated for these new treatments to reach the markets in Europe.

Scrip

Quick Listen: Scrip's Five Must-Know Things

By Ian Haydock 03 Sep 2020

Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.

In Vivo, Scrip

Webinar: Is Biopharma Fit For the New Decade?

11 Mar 2020

Download your article pack now for a glimpse of some of the topics that will be covered by our panel of experts during the “Is Biopharma Fit for the New Decade?” webinar.

Adoptive Cell Therapy

03 Feb 2020

Citeline recently introduced a new Therapeutic Class called "Adoptive cell therapy", enabling more granular searching capabilities to hone in on this exciting cancer immunotherapy that is expanding the horizon of personalized medicine

Pink Sheet

Zolgensma Data Integrity Fallout

06 Nov 2019

Novartis finds itself facing possible criminal or civil action for admitted data manipulation on its application for Zolgensma, a gene therapy used to treat children with spinal muscular atrophy (SMA) – manipulation disclosed only after FDA approval. Pink Sheet was the first to report on the drug’s loss of EU accelerated assessment, nearly 3 weeks before the pharma giant admitted to submitting falsified data to FDA. Follow the scandal and anticipate its implications on the industry with Pink Sheet’s coverage and timeline.

Datamonitor Healthcare

Webinar: Outlook for NASH Therapies and Market Dynamics

By Joseph Haas 01 Nov 2019

Non-alcoholic steatohepatitis (NASH) is poised to become an even greater epidemic and pharma companies of all sizes are competing to be the first to bring a NASH drug to market. Listen to an in-depth discussion about new and repurposed drug exploration treat NASH, as well as deal making, licensing and partnerships activity for the area.